Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt · Delayed Price · Currency is EGP 5.55
+0.10 (1.83%)
At close: Oct 4, 2026
EGX:RMDA Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,282 | 6,660 | 5,022 | 2,459 | 2,892 | 2,400 | |
Market Cap Growth | 76.10% | 32.63% | 104.18% | -14.96% | 20.51% | -18.04% |
Enterprise Value | 13,635 | 8,919 | 5,881 | 3,259 | 3,284 | 3,006 |
Last Close Price | 5.55 | 3.31 | 2.45 | 1.17 | 1.39 | 1.12 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 37.25 | 24.79 | 13.80 | 11.00 | 12.63 | 14.42 |
Forward PE | 16.60 | 9.19 | 10.84 | 7.72 | 9.25 | 10.10 |
PS Ratio | 2.57 | 1.63 | 1.81 | 1.28 | 1.95 | 1.93 |
PB Ratio | 4.75 | 3.01 | 2.42 | 1.39 | 1.90 | 1.78 |
P/TBV Ratio | 9.17 | 6.30 | 3.37 | 2.10 | 2.73 | 2.50 |
P/FCF Ratio | 74.57 | - | - | - | - | 12.72 |
P/OCF Ratio | 38.15 | - | - | - | 98.55 | 9.94 |
PEG Ratio | 0.54 | 0.26 | 0.28 | 0.28 | 0.28 | 0.27 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.11 | 2.18 | 2.12 | 1.70 | 2.21 | 2.41 |
EV/EBITDA Ratio | 12.50 | 8.53 | 7.31 | 6.33 | 8.14 | 9.49 |
EV/EBIT Ratio | 13.55 | 9.27 | 8.11 | 7.31 | 9.60 | 10.96 |
EV/FCF Ratio | 90.12 | - | - | - | - | 15.93 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.02 | 1.09 | 0.76 | 0.63 | 0.61 | 0.65 |
Debt / EBITDA Ratio | 2.21 | 2.28 | 1.94 | 2.15 | 2.28 | 2.75 |
Debt / FCF Ratio | 15.96 | - | - | - | - | 4.66 |
Net Debt / Equity Ratio | 0.97 | 1.07 | 0.63 | 0.45 | 0.33 | 0.30 |
Net Debt / EBITDA Ratio | 2.13 | 2.27 | 1.63 | 1.56 | 1.24 | 1.26 |
Net Debt / FCF Ratio | 15.26 | -11.89 | -3.53 | -5.91 | -99.72 | 2.11 |
Asset Turnover | 0.83 | 0.85 | 0.74 | 0.64 | 0.57 | 0.53 |
Inventory Turnover | 1.97 | 2.37 | 2.82 | 3.13 | 2.52 | 2.37 |
Quick Ratio | 0.36 | 0.38 | 0.53 | 0.54 | 0.62 | 0.76 |
Current Ratio | 1.21 | 1.15 | 1.46 | 1.47 | 1.49 | 1.44 |
Return on Equity (ROE) | 14.95% | 14.63% | 20.89% | 15.35% | 17.63% | 14.24% |
Return on Assets (ROA) | 11.91% | 12.47% | 12.04% | 9.30% | 8.24% | 7.34% |
Return on Invested Capital (ROIC) | 15.88% | 17.85% | 18.59% | 14.98% | 13.99% | 12.53% |
Return on Capital Employed (ROCE) | 39.80% | 40.90% | 33.60% | 24.20% | 21.50% | 19.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.67% | 4.48% | 7.71% | 9.96% | 8.49% | 7.54% |
FCF Yield | 1.34% | -3.00% | -7.41% | -5.51% | -0.17% | 7.86% |
Dividend Yield | 0.72% | - | 1.64% | 4.32% | - | - |
Payout Ratio | 70.47% | 63.30% | 31.31% | 6.85% | 9.89% | 8.12% |
Buyback Yield / Dilution | 0.11% | -0.02% | -1.11% | -1.27% | 2.62% | - |
Total Shareholder Return | 0.84% | -0.02% | 0.53% | 3.04% | 2.62% | - |